



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHARLES RIVER LABORATORIES  
INTERNATIONAL, INC.

Dated: February 12, 2007

By: /s/ Joanne P. Acford

-----  
Joanne P. Acford, Corporate Senior Vice  
President, General Counsel and  
Corporate Secretary

Exhibit Index

Exhibit No. -----	Description -----
99.1	Press release dated February 12, 2007.

Charles River Laboratories Announces Fourth-Quarter and  
Full-Year 2006 Results from Continuing Operations

Fourth-Quarter Sales of \$272 Million and Full-Year Sales of \$1.06  
Billion

Fourth-Quarter GAAP EPS of \$0.47 and Non-GAAP EPS of \$0.58

2006 GAAP EPS of \$1.79 and Non-GAAP EPS of \$2.20

Reaffirms Guidance for 2007

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 12, 2007--Charles River Laboratories International, Inc. (NYSE: CRL) today reported fourth-quarter and full-year 2006 financial results. For the fourth quarter, net sales from continuing operations increased 5.2% to \$271.7 million from \$258.2 million in the fourth quarter of 2005. The increase was due primarily to growth in the Preclinical Services segment, which benefited from continuing demand for outsourced preclinical services and the October 2006 acquisition of Northwest Kinetics, as well as increased sales of Research Model Services and In Vitro products. Foreign exchange contributed 2.4% to the net sales growth.

Charles River's results are reported on a fiscal-year basis which is the twelve-month period ending on the last Saturday in December. As a result, the Company periodically reports a 53-week year, with the additional week reported in the fourth quarter. This was the case in 2005, when the fourth quarter of the year included 14 weeks. The fourth quarter of 2006 was a standard 13-week period, so in comparison to the same period in the prior year, the sales growth rate in the fourth quarter of 2006 was reduced by approximately 3-5%.

On a GAAP basis, net income from continuing operations for the fourth quarter of 2006 was \$31.8 million, or \$0.47 per diluted share, compared to \$56.5 million, or \$0.77 per diluted share, for the fourth quarter of 2005. Results for the fourth quarter of 2006 include \$2.5 million, or \$0.02 per share, of stock option expense as a result of the Company's adoption on January 1, 2006, of Statement of Financial Accounting Standards No. 123R (SFAS 123R), "Share-Based Payment."

On a non-GAAP basis, net income from continuing operations was \$39.0 million for the fourth quarter of 2006, compared to \$40.5 million for the same period in 2005. Fourth-quarter diluted earnings per share on a non-GAAP basis were \$0.58, compared to \$0.55 per share in the fourth quarter of 2005, with the increase in earnings per share due primarily to the lower number of shares outstanding. A reconciliation of GAAP to non-GAAP earnings per share for the fourth quarters of both years is as follows:

RECONCILIATION OF GAAP TO NON-GAAP EPS	4Q06	4Q05
EPS from continuing operations (GAAP)	\$0.47	\$0.77
Amortization related to acquisitions	\$0.10	\$0.12
Stock-based compensation related to Inveresk acquisition	\$0.00	\$0.02
Cost savings initiatives	\$0.01	---
Deferred financing cost	---	\$0.02
Repatriation and related deferred tax reversal	---	(\$0.38)
EPS from continuing operations (Non-GAAP)	\$0.58	\$0.55

For 2006, net sales from continuing operations increased by 6.5% to \$1.06 billion, compared to \$993.3 million in 2005. On a GAAP basis, net income from continuing operations for 2006 was \$125.2 million, or \$1.79 per diluted share, compared to \$145.8 million, or \$2.02 per diluted share, for the prior year. In accordance with SFAS 123R, results for 2006 included \$11.7 million, or \$0.10 per share, of stock option expense. On a non-GAAP basis, net income from continuing operations for 2006 was \$154.2 million, or \$2.20 per diluted share, compared to \$157.6 million, or \$2.18 per diluted share, for 2005, with the increase in earnings per share due primarily to the lower number of shares outstanding. Non-GAAP net income from continuing operations in both periods excluded the following charges:

RECONCILIATION OF GAAP TO NON-GAAP EPS	2006	2005
EPS from continuing operations (GAAP)	\$1.79	\$2.02
Amortization related to acquisitions	\$0.34	\$0.45
Stock-based compensation related to Inveresk acquisition	\$0.01	\$0.07
Cost savings initiatives	\$0.06	---
Deferred financing cost	---	\$0.02
Repatriation and related deferred tax reversal	---	(\$0.38)
EPS from continuing operations (Non-GAAP)	\$2.20	\$2.18

James C. Foster, Chairman, President and Chief Executive Officer, said, "The fourth quarter closed an eventful year for Charles River, a year in which we refocused and rededicated ourselves to our core competencies of laboratory animal medicine and science and regulatory compliant preclinical services. We sold or closed non-core businesses, invested heavily in expanding our Preclinical Services and RMS footprints, acquired a first-class Phase I business in Northwest Kinetics, and repurchased 6.0 million shares of our common stock. Our goal was to position ourselves to better support our clients and to take advantage of opportunities in both the research models and services and preclinical markets. We believe we have achieved that goal, and are enthusiastic about our growth prospects in 2007 and beyond."

The Company reports results from continuing operations, which exclude results of the Clinical Phase II - IV business (sold on August 16, 2006) and closure of the Interventional and Surgical Services (ISS) business (announced on May 9, 2006). Those businesses are now reported as discontinued operations, and the Company has reclassified historical comparisons accordingly. The income from discontinued operations was \$3.4 million in the fourth quarter of 2006. Including discontinued operations, net income for the fourth quarter of 2006 was \$35.2 million, or \$0.52 per diluted share, compared to consolidated net income of \$50.4 million, or \$0.69 per diluted share, in the fourth quarter of 2005. For the full year, the loss from discontinued operations was \$181.0 million, due primarily to a goodwill impairment and income tax expense related to the sale of the Clinical Services Phase II - IV business, and asset impairments and operating losses incurred by the Interventional and Surgical Services business. Including discontinued operations, the net loss for 2006 was \$55.8 million, or \$0.80 per diluted share, compared to consolidated net income of \$142.0 million, or \$1.96 per diluted share, in 2005.

#### Research Models and Services (RMS)

Sales for the RMS segment were \$127.7 million in the fourth quarter of 2006, an increase of 1.6% from \$125.6 million in the fourth quarter of 2005. The quarter-over-quarter growth rate was negatively impacted by approximately 3-5% due to the extra week included in the results for the fourth quarter of 2005. Research Model Services sales increased, as did In Vitro sales which benefited from sales of core products and the PTS. As expected, fourth-quarter sales of large research models were below the fourth quarter of the prior year due to an extended quarantine, which was completed in mid-December.

In the fourth quarter of 2006, the RMS segment's operating margin was lower than in the fourth quarter of 2005, primarily reflecting lower operating income in Japan compared to the prior year which included a one-time insurance settlement, lower sales of large research models, and \$1.1 million of stock compensation expense associated with the adoption of SFAS 123R. The GAAP operating margin was 25.6%, compared to 30.0% for the same period in 2005. On a non-GAAP basis, which excluded charges of \$0.8 million for cost savings initiatives and \$0.2 million for acquisition-related amortization, the operating margin was 26.3%, compared to 30.4% for the same period in the prior year. Costs of SFAS 123R reduced the fourth-quarter 2006 GAAP and non-GAAP operating margins by 0.9%.

For 2006, RMS net sales were \$515.0 million, a 2.4% increase over \$503.2 million for 2005. Growth was driven primarily by sales of North America Research Models and by In Vitro products. The GAAP operating margin was 28.7% compared to 31.8% in 2005. On a non-GAAP basis, which excluded \$3.1 million for cost-saving initiatives and \$0.5 million for acquisition-related amortization, the operating margin was 29.4%, compared to 31.9% in 2005. Costs of \$4.7 million related to SFAS 123R

reduced the GAAP and non-GAAP operating margins for 2006 by approximately 0.9%.

#### Preclinical Services

Results for the Preclinical Services segment now include the Phase I Clinical business, and historical results have been restated accordingly.

Fourth-quarter net sales for the Preclinical Services segment were \$144.1 million, an increase of 8.7% from the \$132.6 million in the fourth quarter of 2005. The quarter-over-quarter growth rate was negatively impacted by approximately 3-5% due to the extra week included in the results for the fourth quarter of 2005. Sales were driven by continuing strong demand for general and specialty toxicology services by pharmaceutical and biotechnology customers, and the addition of the Northwest Kinetics Phase I clinical services business.

The GAAP operating margin improved to 16.0% from 12.2%, as higher sales and improved operating efficiencies and lower amortization offset the \$1.9 million, or a 1.3% operating margin reduction, of stock compensation costs associated with the adoption of SFAS 123R. On a non-GAAP basis, which excludes \$9.6 million of acquisition-related amortization and \$0.1 million for cost saving initiatives, the fourth-quarter operating margin improved to 22.7% compared to 21.4% for the fourth quarter of 2005. On a non-GAAP basis, stock compensation costs in the fourth quarter were \$1.8 million, or an operating margin reduction of 1.2%. The difference between GAAP and non-GAAP stock compensation expense was related to the Inveresk acquisition.

Preclinical Services net sales in 2006 were \$543.4 million, an increase of 10.9% from \$490.2 million for the prior year, due to continuing strong demand for drug discovery and development services by pharmaceutical and biotechnology customers and to moderate capacity expansion at certain of the Company's Preclinical Services sites. The GAAP operating margin was 15.2% compared to 13.9%, with stock compensation costs accounting for \$7.4 million, or a 1.4% reduction in the operating margin. On a non-GAAP basis, the operating margin was 22.6% in 2006, compared to 23.3% in the year-ago period. For 2006, the cost of SFAS 123R was \$7.2 million on a non-GAAP basis, which reduced the non-GAAP operating margin by 1.3%.

#### Stock Repurchase Program

Charles River presently has a stock repurchase authorization in place from its Board of Directors which provides for the purchase of up to \$300.0 million of its common stock. In the fourth quarter of 2006, under a Rule 10b5-1 purchase plan, the Company repurchased approximately 77,000 shares of common stock for \$3.3 million. In 2006, the Company repurchased a total of 6.0 million shares for \$247.2 million. Combined with previous purchases made in 2005, the Company has repurchased a total of approximately 6.4 million shares at a cost of \$264.7 million. There is currently a balance of approximately \$35.3 million available for repurchases under the current authorization.

As of December 30, 2006, Charles River had approximately 66.9 million shares of common stock outstanding.

#### 2007 Guidance

The Company reaffirms its forward-looking guidance based on continuing operations for 2007, which was originally provided on December 13, 2006.

#### 2007 GUIDANCE (from continuing operations)

Net sales growth (in %)	9% - 12%
Sales (\$ in millions)	\$1,160 - \$1,190
GAAP EPS estimate	\$2.11 - \$2.21
Acquisition-related amortization	\$0.32
Non-GAAP EPS estimate	\$2.43 - \$2.53

Charles River Laboratories has scheduled a live webcast on Tuesday, February 13, at 8:30 a.m. ET to discuss matters relating to this press release. To participate, please go to [ir.criver.com](http://ir.criver.com) and select the webcast link. You can also find the associated slide presentation and reconciliations to comparable GAAP measures on the website. The webcast will be available until 5:00 p.m. ET on February 27, 2007.

#### Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share from continuing operations, which exclude cost savings initiatives, costs associated with repatriation of accumulated income under the American Jobs Creation Act of 2004, amortization of intangible assets and other charges related to our acquisitions. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. There are limitations in using non-GAAP financial measures, as they are not prepared in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities, such as business acquisitions, happen infrequently and the underlying costs associated with such activities do not recur. Non-GAAP results also allow investors to compare the Company's operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in the text of this press release, and can also be found on the Company's website at [ir.criver.com](http://ir.criver.com).

#### Caution Concerning Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding our projected 2007 earnings; the future demand for drug discovery and development products and services, including the outsourcing of these services; the impact of specific actions intended to improve overall operating efficiencies and profitability; expectations regarding stock repurchases; the timing of the opening of new and expanded facilities; future cost reduction activities by our customers; and Charles River's future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to sales growth. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: a decrease in research and development spending, a decrease in the level of outsourced services, or other cost reduction actions by our customers; the ability to convert backlog to sales; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on March 14, 2006, as well as other filings we make

with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.

#### About Charles River Laboratories

Charles River Laboratories based in Wilmington, Massachusetts, partners with global pharmaceutical and biotechnology companies, government agencies and leading academic institutions to advance the drug discovery and development process, bringing drugs to market faster and more efficiently. Charles River's 8,000 employees serve clients worldwide. For more information on Charles River, visit our website at [www.criver.com](http://www.criver.com).

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)  
(dollars in thousands, except for per share data)

	Three Months Ended		Twelve Months Ended	
	December 30, 2006	December 31, 2005	December 30, 2006	December 31, 2005
Total net sales	\$271,725	\$258,199	\$1,058,385	\$993,328
Cost of products sold and services provided	169,995	162,244	651,778	603,624
Gross margin	101,730	95,955	406,607	389,704
Selling, general and administrative	46,819	40,485	180,795	157,999
Amortization of intangibles	9,757	12,428	37,639	47,011
Operating income	45,154	43,042	188,173	184,694
Interest income (expense)	(2,309)	(5,665)	(12,590)	(20,629)
Other income (expense)	1,624	597	981	(177)
Income before income taxes and minority interests	44,469	37,974	176,564	163,888
Provision for income taxes	12,568	(18,965)	49,738	16,261
Income before minority interests	31,901	56,939	126,826	147,627
Minority interests	(109)	(392)	(1,605)	(1,838)
Income from continuing operations	31,792	56,547	125,221	145,789
Income (loss) from discontinued businesses, net of tax	3,397	(6,129)	(181,004)	(3,790)
Net income (loss)	\$35,189	\$50,418	\$ (55,783)	\$141,999
Earnings (loss) per common share				
Basic:				
Continuing operations	\$0.48	\$0.79	\$1.82	\$2.09
Discontinued operations	\$0.05	\$ (0.09)	\$ (2.63)	\$ (0.05)
Net income	\$0.53	\$0.70	\$ (0.81)	\$2.04
Diluted:				
Continuing operations	\$0.47	\$0.77	\$1.79	\$2.02
Discontinued operations	\$0.05	\$ (0.08)	\$ (2.59)	\$ (0.05)
Net income	\$0.52	\$0.69	\$ (0.80)	\$1.96
Weighted average number of common shares outstanding				
Basic	66,257,695	71,775,081	68,945,622	69,730,056
Diluted	67,450,735	73,161,997	69,948,032	72,902,385

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)  
(dollars in thousands)

	December 30, 2006	December 31, 2005
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$175,380	\$114,821
Trade receivables, net	202,658	171,259
Inventories	72,362	65,128
Other current assets	44,363	26,858
Current assets of discontinued businesses	6,330	41,256
	-----	-----
Total current assets	501,093	419,322
Property, plant and equipment, net	534,745	387,501
Goodwill, net	1,119,309	1,097,590
Other intangibles, net	160,204	175,021
Deferred tax asset	107,498	68,046
Other assets	133,944	34,709
Long-term assets of discontinued businesses	751	356,020
	-----	-----
Total assets	\$2,557,544	\$2,538,209
	=====	=====
<b>Liabilities and Shareholders' Equity</b>		
<b>Current liabilities</b>		
Current portion of long-term debt	\$24,143	\$36,263
Accounts payable	28,223	28,727
Accrued compensation	41,651	38,238
Deferred income	93,197	95,564
Accrued liabilities	41,991	38,625
Other current liabilities	25,625	43,581
Current liabilities of discontinued businesses	3,667	30,414
	-----	-----
Total current liabilities	258,497	311,412
Long-term debt	547,918	259,902
Other long-term liabilities	146,695	116,503
Long-term liabilities of discontinued businesses	-	13,661
	-----	-----
Total liabilities	953,110	701,478
	-----	-----
Minority interests	9,223	9,718
Total shareholders' equity	1,595,211	1,827,013
	-----	-----
Total liabilities and shareholders' equity	\$2,557,544	\$2,538,209
	=====	=====

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.  
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)  
(dollars in thousands)

	Three Months Ended		Twelve Months Ended	
	December 30, 2006	December 31, 2005	December 30, 2006	December 31, 2005
<b>Research Models and Services</b>				
Net sales	\$127,651	\$125,602	\$514,999	\$503,167
Gross margin	50,358	51,254	214,125	215,534
Gross margin as a % of net sales	39.4%	40.8%	41.6%	42.8%
Operating income	32,619	37,685	147,789	159,756
Operating income as a % of net sales	25.6%	30.0%	28.7%	31.8%
Depreciation and amortization	5,345	5,215	20,802	20,015
Capital expenditures	14,737	7,183	27,018	24,558
<b>Preclinical Services</b>				
Net sales	\$144,074	\$132,597	\$543,386	\$490,161
Gross margin	51,372	44,701	192,482	174,170
Gross margin as a % of net sales	35.7%	33.7%	35.4%	35.5%
Operating income	23,034	16,205	82,323	67,918



Operating income as a % of net sales	16.0%	12.2%	15.2%	13.9%
Depreciation and amortization	16,482	17,689	61,784	67,920
Capital expenditures	67,249	18,087	154,728	69,885

Unallocated Corporate Overhead	\$ (10,499)	\$ (10,848)	\$ (41,939)	\$ (42,980)
--------------------------------	-------------	-------------	-------------	-------------

Total				
Net sales	\$271,725	\$258,199	\$1,058,385	\$993,328
Gross margin	101,730	95,955	406,607	389,704
Gross margin as a % of net sales	37.4%	37.2%	38.4%	39.2%
Operating income (loss)	45,154	43,042	188,173	184,694
Operating income as a % of net sales	16.6%	16.7%	17.8%	18.6%
Depreciation and amortization	21,827	22,904	82,586	87,935
Capital expenditures	81,986	25,270	181,746	94,443

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.  
RECONCILIATION OF GAAP TO NON-GAAP  
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)  
(dollars in thousands)

	Three Months Ended		Twelve Months Ended	
	December 30, 2006	December 31, 2005	December 30, 2006	December 31, 2005
<b>Research Models and Services</b>				
Net sales	\$127,651	\$125,602	\$514,999	\$503,167
Operating income	32,619	37,685	147,789	159,756
Operating income as a % of net sales	25.6%	30.0%	28.7%	31.8%
Add back:				
Amortization related to acquisitions	191	110	461	285
Cost-saving initiatives	781	365	3,115	365
Operating income, excluding specified charges (Non-GAAP)	\$33,591	\$38,160	\$151,365	\$160,406
Non-GAAP operating income as a % of net sales	26.3%	30.4%	29.4%	31.9%
<b>Preclinical Services</b>				
Net sales	\$144,074	\$132,597	\$543,386	\$490,161
Operating income	23,034	16,205	82,323	67,918
Operating income as a % of net sales	16.0%	12.2%	15.2%	13.9%
Add back:				
Amortization related to acquisitions	9,566	12,162	37,178	46,136
Cost-saving initiatives	124	-	3,090	-
Operating income, excluding specified charges (Non-GAAP)	\$32,724	\$28,367	\$122,591	\$114,054
Non-GAAP operating income as a % of net sales	22.7%	21.4%	22.6%	23.3%
<b>Unallocated Corporate Overhead</b>	\$ (10,499)	\$ (10,848)	\$ (41,939)	\$ (42,980)
Add back:				
Amortization related to acquisitions	-	156	-	591
Repatriation	-	1,305	-	1,305
Stock-based compensation related to Inveresk acquisition	70	2,164	634	7,925
Unallocated corporate overhead, excluding specified charges (Non-				



Net income for purposes of calculating earnings per share, excluding specified charges (Non-GAAP)	\$39,028	\$40,513	\$154,185	\$157,593
After-tax equivalent interest expense on 3.5% senior convertible debentures	-	-	-	1,208
	-----	-----	-----	-----
Income for purposes of calculating diluted earnings per share, excluding specified charges (Non-GAAP)	\$39,028	\$40,513	\$154,185	\$158,801
	=====	=====	=====	=====
Weighted average shares outstanding - Basic	66,257,695	71,775,081	68,945,622	69,730,056
Effect of dilutive securities:				
3.5% senior convertible debentures	-	-	-	1,462,474
Stock options and contingently issued restricted stock	1,061,094	1,241,411	867,204	1,424,740
Warrants	131,946	145,505	135,206	285,115
	-----	-----	-----	-----
Weighted average shares outstanding - Diluted	67,450,735	73,161,997	69,948,032	72,902,385
	=====	=====	=====	=====
Basic earnings (loss) per share	\$0.53	\$0.70	\$(0.81)	\$2.04
Diluted earnings (loss) per share	\$0.52	\$0.69	\$(0.80)	\$1.96
Basic earnings per share, excluding specified charges (Non-GAAP)	\$0.59	\$0.56	\$2.24	\$2.26
Diluted earnings per share, excluding specified charges (Non-GAAP)	\$0.58	\$0.55	\$2.20	\$2.18

Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges, consistent with the manner in which management measures and forecasts the Company's performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations.

CONTACT: Investor Contact:  
Charles River Laboratories International, Inc.  
Susan E. Hardy, 781.262.7616  
Corporate Vice President, Investor Relations